A Phase 4 interventional study of Vedolizumab and Adalimumab in Crohn Disease, sponsored by Takeda. Completed at 32 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-07-14.
Sponsored by Takeda · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies testing vedolizumab in Crohn Disease — 10 open to participants now, 12 under way, 7 of them phase 3. vedolizumab · Crohn Disease.
Among the 39 studies testing vedolizumab in Crohn Disease, this one is the 28th largest by enrollment, is one of 5 that started in 2017, is one of 14 in phase 4, and was the 16th registered.
1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.
Browse Crohn Disease studies →10 of the 39 studies testing vedolizumab in Crohn Disease are open now, in 12 countries. Recruiting first, the newest first:
Takeda · Sites in United States, Belgium, Bulgaria and 11 more countries
Ages 2–17
Takeda · Sites in United States
Ages 18–80
Takeda · Sites in United States, Belgium, Bulgaria and 13 more countries
Ages 2–17
Takeda · Sites in United States, Austria, Belgium and 23 more countries
Ages 18–65
Centre Hospitalier Universitaire de Saint Etienne · Sites in France
Ages 18+
By country, each count listing its studies:
vedolizumab: first FDA approval 2014 (ENTYVIO), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 5 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 55 is below the median of 67 across 1,261 interventional studies indexed under Crohn Disease.
Median enrollment 101 across the 39 interventional studies. Of the 22 that completed or were terminated, 18 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 39 have an industry lead sponsor. The 10 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
86 studies in Crohn Disease by Takeda: 12 open now, 14 under way, 7 of them phase 3. Of 66 finished, 37 (56%) have results posted.
Among the 86 studies in Crohn Disease by Takeda, this one is the 35th largest by enrollment of the 51 interventional ones that give a count, is one of 7 that started in 2017, is one of 10 in phase 4, and was the 24th registered.
Takeda’s Crohn Disease studies by the year they started, since 2000.
5 of the studies testing vedolizumab in Crohn Disease that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06227910Phase 3TakedaA Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease | 2027-06-08 |
| NCT04779320Phase 3TakedaA Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD) | 2027-09-13 |
| NCT06581328TakedaA Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting | 2027-05-01 |
| NCT06045754TakedaA Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease | 2027-06-28 |
| NCT06180382Centre Hospitalier Universitaire de Saint EtienneComparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration. | 2027-10-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 39 studies testing vedolizumab in Crohn Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 86 in Crohn Disease:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the effect of triple combination therapy with an anti-integrin (vedolizumab intravenous [IV]), a tumor necrosis factor (TNF) antagonist (adalimumab subcutaneously [SC]), and an immunomodulator (oral methotrexate) on endoscopic remission in participants with newly-diagnosed CD stratified at higher risk for complications.
The drug being tested in this study is called vedolizumab. Vedolizumab is being tested to treat people who have CD. This study will look at the endoscopic remission and mucosal healing of gastrointestinal tract of people who take vedolizumab as triple combination therapy with adalimumab and methotrexate.
The study will enroll approximately 60 participants. Participants will receive triple combination therapy which includes:
All participants will receive vedolizumab intravenous infusion on Weeks 0, 2, 6, 14 and 22 along with adalimumab 160 mg, subcutaneous injection at Week 0, 80 mg at Week 2, then 40 mg once at Week 4 and every 2 weeks thereafter until Week 26 along with methotrexate tablets orally, once weekly from Weeks 0 up to Week 34. In monotherapy phase, all participants will receive vedolizumab intravenous infusion once at Weeks 30, 38, 46, 54, 62, 70, 78, 86, 94 and 102.
This multi-center trial will be conducted in the United States and Canada. The overall time to participate in this study is 128 weeks. Participants will make multiple visits to the clinic, plus a final visit 18 weeks after last dose of study drug for a safety follow-up assessment. Participants will also participate in a long-term safety questionnaire, by phone, at 26 weeks (6 months) from the last dose of study drug.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Gastrointestinal (GI) Exclusion Criteria
In Triple Combination Therapy Phase, vedolizumab 300 mg, intravenous (IV) infusion, once at Weeks 0, 2, 6, 14 and 22, with adalimumab 160 mg subcutaneously (SC), once at Week 0, then 80 mg once at Week 2, then 40 mg once at Week 4 and every 2 weeks thereafter until Week 26 along with oral methotrexate 15 mg tablets orally once weekly from Weeks 0 up to Week 34. In Monotherapy Phase, vedolizumab 300 mg IV infusion once at Weeks 30, 38, 46, 54, 62, 70, 78, 86, 94 and 102.
Drug: Vedolizumab · Drug: Adalimumab · Drug: Methotrexate
Vedolizumab intravenous infusion.
Also known as: Entyvio, MLN0002 IV
Adalimumab injection for subcutaneous use.
Also known as: Humira
Methotrexate oral tablets.
Percentage of Participants Achieving Endoscopic Remission at Week 26
Endoscopic remission was defined as simple endoscopic score for Crohn's Disease (SES-CD) scale score from 0-2. The SES-CD evaluated 4 endoscopic variables: ulcer size, proportion of the surface area that was ulcerated, proportion of the surface area affected, and stenosis in 5 colonic segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The score for each endoscopic variable was the sum of values obtained for each segment. The SES-CD total was the sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease.
Time frame: Week 26
Percentage of Participants Achieving Endoscopic Healing at Week 26
Endoscopic healing was defined as SES-CD score ≤4 and reduction from Baseline in SES-CD score of at least 2 points and no individual SES-CD subscore \>1. The SES-CD evaluated 4 endoscopic variables: ulcer size, proportion of the surface area that is ulcerated, proportion of the surface area affected, and stenosis in 5 colonic segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The score for each endoscopic variable was the sum of values obtained for each segment. The SES-CD total was the sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease. Percentages are rounded off to single decimal.
Time frame: Week 26
Percentage of Participants Achieving Endoscopic Response at Week 26
Endoscopic response was defined as 50% reduction in SES-CD score from Baseline. The SES-CD evaluated 4 endoscopic variables: ulcer size, percentage of the surface area that is ulcerated, percentage of the surface area affected, and stenosis in 5 colonic segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The score for each endoscopic variable was sum of values obtained for each segment. The SES-CD total was the sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease. Percentages are rounded off to single decimal.
Time frame: Week 26
Change From Baseline in SES-CD Score at Week 26
The SES-CD evaluated 4 endoscopic variables: ulcer size, proportion of the surface area that is ulcerated, proportion of the surface area affected, and stenosis in 5 colonic segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The score for each endoscopic variable was the sum of values obtained for each segment. The SES-CD total was the sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease. Negative change indicates improvement.
Time frame: Baseline and Week 26
Percentage of Participants Achieving Deep Remission at Week 26
Deep remission was defined as Crohn's disease activity index (CDAI) score \<150 and SES-CD score from 0-2. CDAI was scoring system for the assessment of CD activity, index values of 150 and below were associated with quiescent disease; values above that indicated active disease and values above 450 were seen with extremely severe disease. The SES-CD evaluated 4 endoscopic variables: ulcer size, percentage of the surface area that is ulcerated, percentage of the surface area affected, and stenosis in 5 colonic segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The score for each endoscopic variable was sum of values obtained for each segment. The SES-CD total was sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease. Percentages are rounded off to single decimal.
Time frame: Week 26
Percentage of Participants Achieving Clinical Remission and Endoscopic Response as a Measure of Mucosal Healing at Week 26
Clinical remission was defined as CDAI score \<150. Endoscopic response was defined as 50% reduction in SES-CD score from Baseline, as mucosal healing. CDAI was scoring system for assessment of CD activity, index values of 150 and below are associated with quiescent disease; values above that indicated active disease and values above 450 were seen with extremely severe disease. The SES-CD evaluated 4 endoscopic variables: ulcer size, percentage of the surface area that is ulcerated, percentage of the surface area affected, and stenosis in 5 colonic segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The SES-CD total was sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease. Percentages are rounded off to single decimal.
Time frame: Week 26
Percentage of Participants Achieving Clinical Remission at Weeks 10 and 26
Clinical remission was defined as CDAI score \<150. CDAI was scoring system for the assessment of CD activity, index values of 150 and below were associated with quiescent disease; values above that indicated active disease and values above 450 were seen with extremely severe disease. Percentages are rounded off to single decimal.
Time frame: Weeks 10 and 26
Percentage of Participants Achieving Clinical Response at Weeks 10 and 26
Clinical response was defined as ≥100-point decrease in CDAI score. CDAI was scoring system for the assessment of CD activity, index values of 150 and below were associated with quiescent disease; values above that indicated active disease and values above 450 were seen with extremely severe disease. Percentages are rounded off to single decimal.
Time frame: Weeks 10 and 26
Change From Baseline in C-reactive Protein (CRP) Levels at Weeks 10 and 26
The change between the CRP levels were collected at Weeks 10 and 26 relative to Baseline. Negative change indicates improvement.
Time frame: Baseline, Weeks 10 and 26
Change From Baseline in Fecal Calprotectin Concentrations at Weeks 10, 14, 26, 52, 78, and 102
The change between the fecal calprotectin concentrations collected at Weeks 10, 14, 26, 52, 78, and 102 relative to Baseline were reported. Baseline is defined as the last observation prior to the first dose of the study drug.
Time frame: Baseline, Weeks 10, 14, 26, 52, 78 and 102
Percentage of Participants Achieving Clinical Remission and CRP <5 Milligram Per Liter (mg/L) at Weeks 26, 52, 78, and 102
Clinical remission was defined as CDAI score \<150 and CRP level \<5 mg/L in participants with elevated CRP level at Baseline. CDAI was scoring system for the assessment of CD activity, index values of 150 and below were associated with quiescent disease; values above that indicate active disease and values above 450 were seen with extremely severe disease. Percentages are rounded off to single decimal.
Time frame: Weeks 26, 52, 78 and 102
Percentage of Participants Using Oral Corticosteroids at Baseline Who Have Discontinued Corticosteroids and Are in Clinical Remission at Weeks 10, 26, and 102
Percentage of participants using oral corticosteroids at Baseline who had discontinued corticosteroids and were in clinical remission at weeks 10, 26, and 102 were reported. Clinical remission was defined as CDAI score \<150. CDAI was scoring system for the assessment of CD activity, index values of 150 and below are associated with quiescent disease; values above that indicate active disease and values above 450 were seen with extremely severe disease. Percentages are rounded off to single decimal.
Time frame: Weeks 10, 26 and 102
Percentage of Participants Maintaining Clinical Remission at Weeks 52, 78, and 102
Clinical remission was defined as CDAI score \<150. Clinical remission was defined as CDAI score \<150. CDAI was scoring system for the assessment of CD activity, index values of 150 and below are associated with quiescent disease; values above that indicated active disease and values above 450 were seen with extremely severe disease. Percentages are rounded off to single decimal.
Time frame: Weeks 52, 78 and 102
Percentage of Participants Maintaining Clinical Response at Weeks 52, 78, and 102
Clinical response was defined as ≥100-point decrease in CDAI score. CDAI was scoring system for the assessment of CD activity, index values of 150 and below were associated with quiescent disease; values above that indicated active disease and values above 450 were seen with extremely severe disease. Percentages are rounded off to single decimal.
Time frame: Weeks 52, 78 and 102
Percentage of Participants Maintaining Endoscopic Remission at Week 102
Endoscopic remission was defined as SES-CD score 0-2. The SES-CD evaluated 4 endoscopic variables: ulcer size, percentage of the surface area that is ulcerated, percentage of the surface area affected, and stenosis in 5 colonic segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The score for each endoscopic variable was sum of values obtained for each segment. The SES-CD total was the sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicated more severe disease. Percentages are rounded off to single decimal.
Time frame: Week 102
Percentage of Participants Maintaining Deep Remission at Week 102
Deep remission was defined as CDAI score \<150 and SES-CD score 0-2. Clinical remission was defined as CDAI score \<150. CDAI was scoring system for the assessment of CD activity, index values of 150 and below are associated with quiescent disease; values above that indicated active disease and values above 450 were seen with extremely severe disease. The SES-CD evaluated 4 endoscopic variables: ulcer size, percentage of the surface area that is ulcerated, percentage of the surface area affected, and stenosis in 5 colonic segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The SES-CD total was the sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease. Percentages are rounded off to single decimal.
Time frame: Week 102
Percentage of Participants Maintaining Endoscopic Healing at Week 102
Endoscopic healing was defined as SES-CD score \<=4 and reduction from Baseline in SES-CD score of at least 2 points and no individual SES-CD subscore \>1. The SES-CD evaluated 4 endoscopic variables: ulcer size, percentage of the surface area that is ulcerated, percentage of the surface area affected, and stenosis in 5 colonic segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The score for each endoscopic variable was sum of values obtained for each segment. The SES-CD total was the sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease. Percentages are rounded off to single decimal.
Time frame: Week 102
Percentage of Participants Maintaining Endoscopic Response at Week 102
Endoscopic response was defined as 50% reduction in SES-CD score from Baseline. The SES-CD evaluated 4 endoscopic variables: ulcer size, percentage of the surface area that is ulcerated, percentage of the surface area affected, and stenosis in 5 colonic segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The score for each endoscopic variable was sum of values obtained for each segment. The SES-CD total was the sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease.
Time frame: Week 102
Percentage of Participants Maintaining Clinical Remission and Endoscopic Response as a Measure of Mucosal Healing at Week 102
Clinical remission is defined as CDAI score \<150. Endoscopic response defined as 50% reduction in SES-CD score from Baseline, as mucosal healing. CDAI is scoring system for assessment of CD activity, index values of 150 and below are associated with quiescent disease; values above that indicate active disease and values above 450 are seen with extremely severe disease. The SES-CD evaluates 4 endoscopic variables (ulcer size, percentage of the surface area that is ulcerated, percentage of the surface area affected, and stenosis in 5 colonic segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The SES-CD total is sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease. Percentages are rounded off to the nearest decimal value.
Time frame: Week 102
Percentage of Participants With First Exacerbation of CD
First exacerbation of CD after 26 weeks was defined as either: 1) a CDAI increase of \>70 from the prior visit on 2 occasions separated by a 2-week interval, objective evidence of disease activity by colonoscopy or CRP above normal OR 2) fecal calprotectin \>250 microgram per gram (mcg/g) alone. CDAI was scoring system for the assessment of CD activity, index values of 150 and below were associated with quiescent disease; values above that indicated active disease and values above 450 are seen with extremely severe disease. Percentages are rounded off to the nearest decimal value.
Time frame: After 26 Weeks up to Week 120
Participants took part in the study at 23 investigative sites in Canada and United States from 18 April 2017 to 05 July 2022.
| Milestone | Vedolizumab 300 mg (IV) + Adalimumab 160-80-40 mg (SC) + Methotrexate 15 mg (Oral) |
|---|---|
| Started | 55 |
| Triple combination therapy | 55 |
| Monotherapy | 45 |
| Safety follow-up | 53 |
| Completed | 16 |
| Not completed | 39 |
| Withdrew: Pretreatment event/adverse event | 9 |
| Withdrew: Lost to follow-up | 4 |
| Withdrew: Voluntary withdrawal | 8 |
| Withdrew: Site termination | 1 |
| Withdrew: Lack of efficacy | 16 |
| Withdrew: Reason not specified | 1 |
Endoscopic remission was defined as simple endoscopic score for Crohn's Disease (SES-CD) scale score from 0-2. The SES-CD evaluated 4 endoscopic variables: ulcer size, proportion of the surface area that was ulcerated, proportion of the surface area affected, and stenosis in 5 colonic segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The score for each endoscopic variable was the sum of values obtained for each segment. The SES-CD total was the sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease.
| percentage of participants | Vedolizumab 300 mg (IV) + Adalimumab 160-80-40 mg (SC) + Methotrexate 15 mg (Oral) |
|---|---|
| Percentage of Participants Achieving Endoscopic Remission at Week 26 | 34.5 (21.1 to 48.0) |
Endoscopic healing was defined as SES-CD score ≤4 and reduction from Baseline in SES-CD score of at least 2 points and no individual SES-CD subscore \>1. The SES-CD evaluated 4 endoscopic variables: ulcer size, proportion of the surface area that is ulcerated, proportion of the surface area affected, and stenosis in 5 colonic segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The score for each endoscopic variable was the sum of values obtained for each segment. The SES-CD total was the sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease. Percentages are rounded off to single decimal.
| percentage of participants | Vedolizumab 300 mg (IV) + Adalimumab 160-80-40 mg (SC) + Methotrexate 15 mg (Oral) |
|---|---|
| Percentage of Participants Achieving Endoscopic Healing at Week 26 | 43.6 (29.6 to 57.7) |
Endoscopic response was defined as 50% reduction in SES-CD score from Baseline. The SES-CD evaluated 4 endoscopic variables: ulcer size, percentage of the surface area that is ulcerated, percentage of the surface area affected, and stenosis in 5 colonic segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The score for each endoscopic variable was sum of values obtained for each segment. The SES-CD total was the sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease. Percentages are rounded off to single decimal.
| percentage of participants | Vedolizumab 300 mg (IV) + Adalimumab 160-80-40 mg (SC) + Methotrexate 15 mg (Oral) |
|---|---|
| Percentage of Participants Achieving Endoscopic Response at Week 26 | 56.4 (42.3 to 70.4) |
The SES-CD evaluated 4 endoscopic variables: ulcer size, proportion of the surface area that is ulcerated, proportion of the surface area affected, and stenosis in 5 colonic segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The score for each endoscopic variable was the sum of values obtained for each segment. The SES-CD total was the sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease. Negative change indicates improvement.
| score on a scale | Vedolizumab 300 mg (IV) + Adalimumab 160-80-40 mg (SC) + Methotrexate 15 mg (Oral) |
|---|---|
| Baseline | 12.6 ± 5.67 |
| Change From Baseline at Week 26 | -8.9 ± 7.29 |
Deep remission was defined as Crohn's disease activity index (CDAI) score \<150 and SES-CD score from 0-2. CDAI was scoring system for the assessment of CD activity, index values of 150 and below were associated with quiescent disease; values above that indicated active disease and values above 450 were seen with extremely severe disease. The SES-CD evaluated 4 endoscopic variables: ulcer size, percentage of the surface area that is ulcerated, percentage of the surface area affected, and stenosis in 5 colonic segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The score for each endoscopic variable was sum of values obtained for each segment. The SES-CD total was sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease. Percentages are rounded off to single decimal.
| percentage of participants | Vedolizumab 300 mg (IV) + Adalimumab 160-80-40 mg (SC) + Methotrexate 15 mg (Oral) |
|---|---|
| Percentage of Participants Achieving Deep Remission at Week 26 | 21.8 (10.0 to 33.6) |
Clinical remission was defined as CDAI score \<150. Endoscopic response was defined as 50% reduction in SES-CD score from Baseline, as mucosal healing. CDAI was scoring system for assessment of CD activity, index values of 150 and below are associated with quiescent disease; values above that indicated active disease and values above 450 were seen with extremely severe disease. The SES-CD evaluated 4 endoscopic variables: ulcer size, percentage of the surface area that is ulcerated, percentage of the surface area affected, and stenosis in 5 colonic segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The SES-CD total was sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease. Percentages are rounded off to single decimal.
| percentage of participants | Vedolizumab 300 mg (IV) + Adalimumab 160-80-40 mg (SC) + Methotrexate 15 mg (Oral) |
|---|---|
| Percentage of Participants Achieving Clinical Remission and Endoscopic Response as a Measure of Mucosal Healing at Week 26 | 38.2 (24.4 to 51.9) |
Clinical remission was defined as CDAI score \<150. CDAI was scoring system for the assessment of CD activity, index values of 150 and below were associated with quiescent disease; values above that indicated active disease and values above 450 were seen with extremely severe disease. Percentages are rounded off to single decimal.
| percentage of participants | Vedolizumab 300 mg (IV) + Adalimumab 160-80-40 mg (SC) + Methotrexate 15 mg (Oral) |
|---|---|
| Week 10 | 60.0 (46.1 to 73.9) |
| Week 26 | 54.5 (40.5 to 68.6) |
Clinical response was defined as ≥100-point decrease in CDAI score. CDAI was scoring system for the assessment of CD activity, index values of 150 and below were associated with quiescent disease; values above that indicated active disease and values above 450 were seen with extremely severe disease. Percentages are rounded off to single decimal.
| percentage of participants | Vedolizumab 300 mg (IV) + Adalimumab 160-80-40 mg (SC) + Methotrexate 15 mg (Oral) |
|---|---|
| Week 10 | 49.1 (35.0 to 63.2) |
| Week 26 | 43.6 (29.6 to 57.7) |
The change between the CRP levels were collected at Weeks 10 and 26 relative to Baseline. Negative change indicates improvement.
| milligrams per liter (mg/L) | Vedolizumab 300 mg (IV) + Adalimumab 160-80-40 mg (SC) + Methotrexate 15 mg (Oral) |
|---|---|
| Baseline | 7.60 (0.6 to 135.8) |
| Change From Baseline at Week 10 | -4.80 (-84.0 to 29.7) |
| Change From Baseline at Week 26 | -5.50 (-79.3 to 104.3) |
The change between the fecal calprotectin concentrations collected at Weeks 10, 14, 26, 52, 78, and 102 relative to Baseline were reported. Baseline is defined as the last observation prior to the first dose of the study drug.
| micrograms per gram | Vedolizumab 300 mg (IV) + Adalimumab 160-80-40 mg (SC) + Methotrexate 15 mg (Oral) | Vedolizumab 300 mg (IV) |
|---|---|---|
| Baseline | 1301.0 (23 to 17707) | 1210.0 (23 to 17707) |
| Change From Baseline at Week 10 | -864.0 (-16406 to 471) | — |
| Change From Baseline at Week 14 | -556.0 (-14742 to 6892) | — |
| Change From Baseline at Week 26 | -860.5 (-7911 to 440) | — |
| Change From Baseline at Week 52 | — | -350.0 (-7365 to 8021) |
| Change From Baseline at Week 78 | — | -396.5 (-7844 to 9434) |
| Change From Baseline at Week 102 | — | -452.0 (-8052 to 106) |
Clinical remission was defined as CDAI score \<150 and CRP level \<5 mg/L in participants with elevated CRP level at Baseline. CDAI was scoring system for the assessment of CD activity, index values of 150 and below were associated with quiescent disease; values above that indicate active disease and values above 450 were seen with extremely severe disease. Percentages are rounded off to single decimal.
| percentage of participants | Vedolizumab 300 mg (IV) + Adalimumab 160-80-40 mg (SC) + Methotrexate 15 mg (Oral) | Vedolizumab 300 mg (IV) |
|---|---|---|
| Week 26 | 51.3 (34.3 to 68.3) | — |
| Week 52 | — | 44.1 (26.0 to 62.3) |
| Week 78 | — | 26.5 (10.2 to 42.8) |
| Week 102 | — | 20.6 (5.5 to 35.7) |
Percentage of participants using oral corticosteroids at Baseline who had discontinued corticosteroids and were in clinical remission at weeks 10, 26, and 102 were reported. Clinical remission was defined as CDAI score \<150. CDAI was scoring system for the assessment of CD activity, index values of 150 and below are associated with quiescent disease; values above that indicate active disease and values above 450 were seen with extremely severe disease. Percentages are rounded off to single decimal.
| percentage of participants | Vedolizumab 300 mg (IV) + Adalimumab 160-80-40 mg (SC) + Methotrexate 15 mg (Oral) | Vedolizumab 300 mg (IV) |
|---|---|---|
| Week 10 | 50.0 (22.4 to 77.6) | — |
| Week 26 | 56.3 (28.8 to 83.7) | — |
| Week 102 | — | 21.4 (0.0 to 46.5) |
Clinical remission was defined as CDAI score \<150. Clinical remission was defined as CDAI score \<150. CDAI was scoring system for the assessment of CD activity, index values of 150 and below are associated with quiescent disease; values above that indicated active disease and values above 450 were seen with extremely severe disease. Percentages are rounded off to single decimal.
| percentage of participants | Vedolizumab 300 mg (IV) |
|---|---|
| Week 52 | 50.0 (30.4 to 69.6) |
| Week 78 | 33.3 (14.8 to 51.9) |
| Week 102 | 20.0 (4.0 to 36.0) |
Clinical response was defined as ≥100-point decrease in CDAI score. CDAI was scoring system for the assessment of CD activity, index values of 150 and below were associated with quiescent disease; values above that indicated active disease and values above 450 were seen with extremely severe disease. Percentages are rounded off to single decimal.
| percentage of participants | Vedolizumab 300 mg (IV) |
|---|---|
| Week 52 | 66.7 (45.7 to 87.6) |
| Week 78 | 45.8 (23.8 to 67.9) |
| Week 102 | 29.2 (8.9 to 49.4) |
Endoscopic remission was defined as SES-CD score 0-2. The SES-CD evaluated 4 endoscopic variables: ulcer size, percentage of the surface area that is ulcerated, percentage of the surface area affected, and stenosis in 5 colonic segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The score for each endoscopic variable was sum of values obtained for each segment. The SES-CD total was the sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicated more severe disease. Percentages are rounded off to single decimal.
| percentage of participants | Vedolizumab 300 mg (IV) |
|---|---|
| Percentage of Participants Maintaining Endoscopic Remission at Week 102 | 27.8 (4.3 to 51.2) |
Deep remission was defined as CDAI score \<150 and SES-CD score 0-2. Clinical remission was defined as CDAI score \<150. CDAI was scoring system for the assessment of CD activity, index values of 150 and below are associated with quiescent disease; values above that indicated active disease and values above 450 were seen with extremely severe disease. The SES-CD evaluated 4 endoscopic variables: ulcer size, percentage of the surface area that is ulcerated, percentage of the surface area affected, and stenosis in 5 colonic segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The SES-CD total was the sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease. Percentages are rounded off to single decimal.
| percentage of participants | Vedolizumab 300 mg (IV) |
|---|---|
| Percentage of Participants Maintaining Deep Remission at Week 102 | 8.3 (0.0 to 28.1) |
Endoscopic healing was defined as SES-CD score \<=4 and reduction from Baseline in SES-CD score of at least 2 points and no individual SES-CD subscore \>1. The SES-CD evaluated 4 endoscopic variables: ulcer size, percentage of the surface area that is ulcerated, percentage of the surface area affected, and stenosis in 5 colonic segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The score for each endoscopic variable was sum of values obtained for each segment. The SES-CD total was the sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease. Percentages are rounded off to single decimal.
| percentage of participants | Vedolizumab 300 mg (IV) |
|---|---|
| Percentage of Participants Maintaining Endoscopic Healing at Week 102 | 34.8 (13.1 to 56.4) |
Endoscopic response was defined as 50% reduction in SES-CD score from Baseline. The SES-CD evaluated 4 endoscopic variables: ulcer size, percentage of the surface area that is ulcerated, percentage of the surface area affected, and stenosis in 5 colonic segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The score for each endoscopic variable was sum of values obtained for each segment. The SES-CD total was the sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease.
| percentage of participants | Vedolizumab 300 mg (IV) |
|---|---|
| Percentage of Participants Maintaining Endoscopic Response at Week 102 | 50.0 (30.4 to 69.6) |
Clinical remission is defined as CDAI score \<150. Endoscopic response defined as 50% reduction in SES-CD score from Baseline, as mucosal healing. CDAI is scoring system for assessment of CD activity, index values of 150 and below are associated with quiescent disease; values above that indicate active disease and values above 450 are seen with extremely severe disease. The SES-CD evaluates 4 endoscopic variables (ulcer size, percentage of the surface area that is ulcerated, percentage of the surface area affected, and stenosis in 5 colonic segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The SES-CD total is sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease. Percentages are rounded off to the nearest decimal value.
| percentage of participants | Vedolizumab 300 mg (IV) |
|---|---|
| Percentage of Participants Maintaining Clinical Remission and Endoscopic Response as a Measure of Mucosal Healing at Week 102 | 19.0 (0.0 to 38.2) |
First exacerbation of CD after 26 weeks was defined as either: 1) a CDAI increase of \>70 from the prior visit on 2 occasions separated by a 2-week interval, objective evidence of disease activity by colonoscopy or CRP above normal OR 2) fecal calprotectin \>250 microgram per gram (mcg/g) alone. CDAI was scoring system for the assessment of CD activity, index values of 150 and below were associated with quiescent disease; values above that indicated active disease and values above 450 are seen with extremely severe disease. Percentages are rounded off to the nearest decimal value.
| percentage of participants | Vedolizumab 300 mg (IV) |
|---|---|
| Percentage of Participants With First Exacerbation of CD | 62.2 (46.9 to 77.5) |
Collected over From the first dose up to EOS (up to 120 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Vedolizumab 300 mg (IV) + Adalimumab 160-80-40 mg (SC) + Methotrexate 15 mg (Oral) | 0/55 (0%) | 6/55 (10.9%) | 36/55 (65.5%) |
| Vedolizumab 300 mg (IV) | 0/45 (0%) | 1/45 (2.2%) | 31/45 (68.9%) |
| Safety Follow-up | 0/53 (0%) | 2/53 (3.8%) | 4/53 (7.5%) |
| Event | Vedolizumab 300 mg (IV) + Adalimumab 160-80-40 mg (SC) + Methotrexate 15 mg (Oral) | Vedolizumab 300 mg (IV) | Safety Follow-up |
|---|---|---|---|
| Small intestinal obstructionGastrointestinal disorders | 2/55 | 0/45 | 1/53 |
| AppendicitisInfections and infestations | 0/55 | 1/45 | 0/53 |
| Abdominal wall abscessInfections and infestations | 0/55 | 0/45 | 1/53 |
| Colonic fistulaGastrointestinal disorders | 0/55 | 0/45 | 1/53 |
| Crohn's diseaseGastrointestinal disorders | 1/55 | 0/45 | 0/53 |
| GastroenteritisInfections and infestations | 1/55 | 0/45 | 0/53 |
| LymphadenopathyBlood and lymphatic system disorders | 1/55 | 0/45 | 0/53 |
| Perirectal abscessInfections and infestations | 1/55 | 0/45 | 0/53 |
| PyrexiaGeneral disorders | 1/55 | 0/45 | 0/53 |
| Event | Vedolizumab 300 mg (IV) + Adalimumab 160-80-40 mg (SC) + Methotrexate 15 mg (Oral) | Vedolizumab 300 mg (IV) | Safety Follow-up |
|---|---|---|---|
| Crohn's diseaseGastrointestinal disorders | 9/55 | 20/45 | 4/53 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 10/55 | 3/45 | 0/53 |
| RashSkin and subcutaneous tissue disorders | 3/55 | 5/45 | 0/53 |
| NasopharyngitisInfections and infestations | 6/55 | 3/45 | 0/53 |
| Abdominal painGastrointestinal disorders | 5/55 | 4/45 | 0/53 |
| HeadacheNervous system disorders | 5/55 | 2/45 | 0/53 |
| C-reactive protein increasedInvestigations | 1/55 | 4/45 | 0/53 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/55 | 4/45 | 0/53 |
| Faecal calprotectin increasedInvestigations | 2/55 | 4/45 | 0/53 |
| FatigueGeneral disorders | 4/55 | 1/45 | 0/53 |
Safety Analysis Set included all participants who received at least 1 dose of study drug.
| Age, Continuous(years) | Vedolizumab 300 mg (IV) + Adalimumab 160-80-40 mg (SC) + Methotrexate 15mg (Oral) |
|---|---|
| Mean | 32.4 ± 12.38 |
| Sex: Female, Male(Participants) | Vedolizumab 300 mg (IV) + Adalimumab 160-80-40 mg (SC) + Methotrexate 15mg (Oral) |
|---|---|
| Female | 24 |
| Male | 31 |
| Ethnicity (NIH/OMB)(Participants) | Vedolizumab 300 mg (IV) + Adalimumab 160-80-40 mg (SC) + Methotrexate 15mg (Oral) |
|---|---|
| Hispanic or Latino | 1 |
| Not Hispanic or Latino | 40 |
| Unknown or Not Reported | 14 |
| Race (NIH/OMB)(Participants) | Vedolizumab 300 mg (IV) + Adalimumab 160-80-40 mg (SC) + Methotrexate 15mg (Oral) |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 4 |
| White | 49 |
| More than one race | 1 |
| Unknown or Not Reported | 0 |
| Height(cm) | Vedolizumab 300 mg (IV) + Adalimumab 160-80-40 mg (SC) + Methotrexate 15mg (Oral) |
|---|---|
| Mean | 171.4 ± 9.55 |
| Weight(kg) | Vedolizumab 300 mg (IV) + Adalimumab 160-80-40 mg (SC) + Methotrexate 15mg (Oral) |
|---|---|
| Mean | 71.87 ± 18.373 |
| Body Mass Index (BMI)(kg/m^2) | Vedolizumab 300 mg (IV) + Adalimumab 160-80-40 mg (SC) + Methotrexate 15mg (Oral) |
|---|---|
| Mean | 24.26 ± 5.029 |
| Region of Enrollment(Participants) | Vedolizumab 300 mg (IV) + Adalimumab 160-80-40 mg (SC) + Methotrexate 15mg (Oral) |
|---|---|
| Canada | 14 |
| United States | 41 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Apr 2017 to primary completion in Sep 2020, 41 months.
Results were first posted in Oct 2021, 1 year after primary completion.
Of 70 phase 4 interventional studies under Crohn Disease, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 68. This study's 41 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Vedolizumab · Adalimumab · Methotrexate